Pfizer secures European approval for Avastin biosimilar
Pfizer’s Zirabev receives approval from the European Commission as a biosimilar to Roche’s Avastin, which brought in sales of CHF1.8bn in Europe during 2018.
Archives for February 19, 2019
Canada rejects biologic suffix addition leaving US only proponent
Health Canada opts not to include the additional suffix after biologics’ non-proprietary name, instead relying on the brand name and products’ identification number.